Citigroup Maintains Buy on BioNTech, Lowers Price Target to $125

Benzinga Newsdesk www.benzinga.com Negative 50.2%

Neg 50.2% Neu 0% Pos 0%

Citigroup analyst Geoff Meacham maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $130 to $125.